Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis.

Radiation oncology (London, England)·2026

Same author

Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.

Hepatology (Baltimore, Md.)·2026

Same author

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy.

Cell reports. Medicine·2025

Same author

Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation.

Nature communications·2025

Same author

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.

JAMA oncology·2024

Same author

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study.

Liver cancer·2024

Search research articles

Related Experiment Video

Updated: May 25, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Targeted therapy for biliary tract cancers.

Jason E Faris¹, Andrew X Zhu

¹Harvard Medical School, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Yawkey 7E, Boston, MA 02114, USA. jfaris@partners.org

Journal of Hepato-Biliary-Pancreatic Sciences

|February 10, 2012

Summary

This summary is machine-generated.

Targeted therapies show promise for biliary tract cancers (BTCs), a group of challenging malignancies. This review highlights recent advancements in targeted agents and upcoming clinical trials for improved BTC treatment.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: May 25, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

Oncology
Gastroenterology
Pharmacology

Background:

Biliary tract cancers (BTCs) are a diverse group of cancers with historically poor outcomes.
Therapeutic development for BTCs was limited by low incidence, tumor heterogeneity, and insufficient clinical trial participation.
The gemcitabine and cisplatin combination chemotherapy, proven effective in the ABC-02 trial, has shifted the treatment landscape.

Purpose of the Study:

To review recent advancements in targeted therapeutics for biliary tract cancers.
To explore targeted agents focusing on key signaling pathways like EGFR, angiogenesis, and MAPK.
To discuss current phase I/II trial data and preview future targeted therapy trials in BTC.

Main Methods:

Review of recent clinical trial data (Phase I and II) for targeted therapies in BTC.
Analysis of targeted agents acting on specific signaling pathways relevant to BTC.
Discussion of emerging therapeutic strategies and future clinical trial designs.

Main Results:

While chemotherapy has improved outcomes, no targeted agents are currently approved for BTC.
Several targeted agents are under investigation, targeting critical pathways like epidermal growth factor receptor (EGFR), angiogenesis, and the mitogen-activated protein kinase (MAPK) pathway.
Early-phase trials are providing valuable data on the safety and efficacy of these novel agents.

Conclusions:

Targeted therapies represent a promising frontier for improving outcomes in biliary tract cancers.
Further research and clinical trials are essential to identify and validate effective targeted agents for BTC treatment.
The development of targeted therapies holds potential to overcome current treatment limitations and improve patient prognosis in BTC.